OR WAIT 15 SECS
Data analysis and clinical trial software specialist, Exploristics, is pleased to announce its plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0, by the end of the summer.
The software offers second-generation simulation capabilities providing a virtual environment for clinical study design and data analysis through the processing power of cloud computing.
KerusCloud 2.0 builds on its capability enabling more realistic clinical trial simulations thanks to a new feature that generates correlated data for sub-groups within a patient population, facilitating the investigation of precision medicine or adaptive development pathways.
This means that clusters of patients in a clinical trial grouped by factors such as genetics, risk factors, and biological sub-types can be looked at in greater detail, enabling clinical development teams to pursue more complex clinical strategies with in-silico design tools.
The latest version also delivers a user experience with simulations that allow its users to explore a greater range of options in a much shorter time period. In addition, increased security features have been added, such as multi-factor authentication.
KerusCloud 2.0 also provides interactive graphical representations that allow users to explore multiple design scenarios for their trial to make informed data-driven decisions aligned to their clinical and business objectives.
Dr Aiden Flynn, CEO of Exploristics, who founded the business in 2009, said: “We’ve already witnessed the profound difference KerusCloud can make to our customers’ clinical trials, with one customer saving $25m and 3 years development time in their clinical development strategy.”
“The updated KerusCloud 2.0 puts clinical development teams at the forefront of complex study design supporting key-decision-making to optimise and accelerate clinical development strategies.”
To support KerusCloud 2.0, Exploristics will be offering enhanced consulting services with a dedicated team of experts available to ensure that customers can reap the full benefit of the new version as they confront the challenges of increasingly complex clinical scenarios.
Dr Flynn continued: “We work continuously to ensure our software can meet the evolving needs of clinical development teams and provide them with the necessary support to implement its unique capabilities for optimising, data-driven clinical trial design.
“Removing barriers to state-of-the-art clinical trial planning is vital to transforming global clinical practice and improving the quality of clinical research and we believe KerusCloud 2.0 will play a key role in that.”
The potential of the KerusCloud platform to transform the speed and efficiency of bringing new medicines to market has been recognized by government bodies and Exploristics was recently awarded a £1m Innovate UK loan to extend its capabilities by integrating it into an intelligent software ecosystem.
The KerusCloud Ecosystem will enable access to clinical data sources to create a knowledge base for selected therapeutic areas and development programs. Evolving with use, the ecosystem will inform and generate study simulations available to date, supporting the complex trial planning now needed in the development of new therapeutic interventions.
For more information on Exploristics visit https://exploristics.com